Overview

4 Week, Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease

Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to determine the safety and tolerability of AZD1446 vs Placebo given as an add-on treatment to Donepezil for 4 weeks in patients with mild to moderate Alzheimer's disease.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Treatments:
Donepezil